Clinical relapse · people with inflammatory bowel disease
High‐treatment‐dose vitamin D (greater than 1000 IU/day) showed no clear difference in clinical relapse at end of study (52 weeks) compared with low‐treatment‐dose vitamin D (400 IU/day to 1000 IU/day) (low certainty).
1 finding from 1 review
Quality of life · people with inflammatory bowel disease
1 finding from 1 review
Withdrawals due to adverse events · people with inflammatory bowel disease
It is very uncertain whether high‐treatment‐dose vitamin D (greater than 1000 IU/day) changes withdrawals due to adverse events compared with low‐treatment‐dose vitamin D (400 IU/day to 1000 IU/day) (very low certainty).
1 finding from 1 review
All‐cause in‐hospital mortality by 36 weeks' postmenstrual ageUnit: number of infants with event · preterm infants with respiratory dysfunction
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Severe ROPUnit: number of infants with event · preterm infants with respiratory dysfunction
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Neurodevelopmental outcomes · preterm infants with respiratory dysfunction
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Time in desired SpO2 rangeScale: 0% to 100% of time · preterm infants with respiratory dysfunction
1 finding from 1 review
Smoking cessation · people who smoke
Higher‐dose showed no clear difference in smoking cessation ‐ 42/44 mg versus 21/22 mg (24‐hour patches) compared with lower‐dose nicotine patch (moderate certainty).
3 findings from 1 review
RR 1.09 [0.93, 1.29]
5 studies · 1655 participants
Moderate
RR 1.19 [1, 1.41]
3 studies · 3446 participants
Moderate
RR 1.48 [1.06, 2.08]
1 study · 537 participants
Moderate
SAEs · people who smoke
Higher‐dose showed no clear difference in overall SAEs ‐ 42/44 mg versus 21/22 mg (24 hr patches) compared with lower‐dose nicotine patch (low certainty).
2 findings from 1 review
Treatment withdrawal · people who smoke
Higher‐dose may leads to higher treatment withdrawals ‐ 42/44 mg versus 21/22 mg (24‐hour patches) compared with lower‐dose nicotine patch (low certainty).
1 finding from 1 review
Treatment withdrawals ‐ 21 mg versus 14 mg (24‐hour patches) · people who smoke
Higher‐dose showed no clear difference in treatment withdrawals ‐ 21 mg versus 14 mg (24‐hour patches) compared with lower‐dose nicotine patch (low certainty).
1 finding from 1 review
Functional ability · people with mild‐to‐moderate dementia (at medium‐term follow‐up)
1 finding from 1 review
Self‐efficacy · people with mild‐to‐moderate dementia (at medium‐term follow‐up)
1 finding from 1 review
Mood: depression (participant self‐report) · people with mild‐to‐moderate dementia (at medium‐term follow‐up)
1 finding from 1 review
QoL · people with mild‐to‐moderate dementia (at medium‐term follow‐up)
1 finding from 1 review
Quality of life: psychological (care partner self‐report) · people with mild‐to‐moderate dementia (at medium‐term follow‐up)
1 finding from 1 review
Functional ability in targeted activities: personal goals ‐ performance (participant self‐report) · people with mild‐to‐moderate dementia (at medium‐term follow‐up)
1 finding from 1 review
Functional ability in targeted activities: personal goals ‐ performance (informant report of participant) · people with mild‐to‐moderate dementia (at medium‐term follow‐up)
1 finding from 1 review
Functional disability (Higher scores indicate higher levels of disability) · chronic pain (excluding headache) in adults
1 finding from 1 review
Quality of life (Higher scores indicate improvement) · chronic pain (excluding headache) in adults
1 finding from 1 review